Advances in IBD Precision Medicine with Therapeutic Drug Monitoring
Gain expert insights from Marla Dubinksy, MD, and Bruce Sands, MD, AGAF, on when to use therapeutic drug monitoring proactively to improve the efficacy of biologic therapy for inflammatory bowel disease (IBD) and reactively to guide decision-making following primary nonresponse or secondary loss of response to a biologic. Offers 1.0 CME.
AGA Expert Exchange: Biosimilars in GI
This blended learning approach provides an overview on the safety and efficacy of biosimilars and how to appropriately incorporate biosimilars into clinical practice via Tweetorial on the basics of biosimilars, a Twitter chat with the experts, an AGA Roundtable panel discussion and an on-demand module. Supported by an independent grant from Amgen Inc., 1.0 CME.
Best of AGA at DDW® 2021: Inflammatory Bowel Disease
Peter Higgins, MD, PhD, AGAF, and Fernando Velayos, MD, AGAF, highlight the best and latest IBD research presented at Digestive Disease Week® (DDW) 2021.
Biosimilars: How to Make the Switch
This four-part panel series, supported by an independent education grant from Pfizer, focuses on real-world practical approaches to the adoption of biosimilars and the data available demonstrating the safety and efficacy of biosimilars in different clinical settings.
Navigating State Step Therapy Laws
Step therapy is an insurance company tool that requires patients to try and fail medications before agreeing to cover the health care provider’s initial treatment recommendation. Largely impacting patients with IBD, this protocol allows insurance companies to disrupt the provider-patient relationship and dictate a patient’s course of treatment. Thankfully, eight states (Illinois, Indiana, Iowa, Minnesota, New Mexico, New York, Texas and West Virginia) have implemented step therapy laws that give GIs additional rights and opportunities to protect their patients. These state-specific education modules provide an overview of each state’s step therapy law and provide step-by-step directions for how providers can leverage step therapy laws to effectively advocate on behalf of their patients.
GI Pop Quiz! IBD
Do you think you know everything there is to know about treating IBD? Take AGA’s GI Pop Quiz! IBD four short quizzes and find out. This activity is supported by independent grants from AbbVie, Ferring and Takeda. Offers 1.0 CME.
Ulcerative Colitis: Applying Guidelines in Practice
David T. Rubin, MD, AGAF, Millie Long, MD, AGAF, and Anita Afzalit, MD, MPH, AGAF, share treatment guidelines and best practices in ulcerative colitis. This activity is supported by educational grants from Amgen and Takeda. Offers 1.25 CME.
Understanding the IBD Patient Journey
Discover how patients see their IBD journey – from realizing that something is wrong to beginning care, obtaining a diagnosis, starting treatment and, ultimately, living with the disease.
And for even more on IBD, be sure to save the date for the sixth annual Crohn’s & Colitis Congress®, taking place Jan. 18-21, 2023, in Denver, Colorado. A partnership of AGA and the Crohn’s & Colitis Foundation, the Congress is the premier conference bringing together and empowering a multidisciplinary community of health care practitioners and researchers to transform IBD care. This comprehensive conference is patient-centered and pairs best practices in clinical care with innovative research.
